Oncology
Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer
Markus Heiss
REFERENCE: ABSTRACT 5001, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
MARKUS HEISS, Klinikum Cologne, Merheim
For patients with malignant ascites as a result of ovarian cancer, a novel intraperitoneal therapy adding the trifunctional antibody catumaxomab to standard paracentesis has prolonged survival, according to a study from Germany that randomly assigned over 100 patients. Sarah Maxwell inteviewed Markus Heiss.
MARKUS HEISS, Klinikum Cologne, Merheim
For patients with malignant ascites as a result of ovarian cancer, a novel intraperitoneal therapy adding the trifunctional antibody catumaxomab to standard paracentesis has prolonged survival, according to a study from Germany that randomly assigned over 100 patients. Sarah Maxwell inteviewed Markus Heiss.
Sibylle Loibl
Catumaxomab for Patients With Platinum Refractory Ovarian Cancer?
REFERENCE: ABSTRACT 5005, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
SIBYLLE LOIBL, German Breast Group, Isenburg, Germany
Intraperitoneal infusion of catumaxomab seemed to show a benefit in patients with platinum refractory epithelial ovarian cancer in a study that found that a higher dose was more beneficial. Sarah Maxwell heard from Sibylle Loibl.
SIBYLLE LOIBL, German Breast Group, Isenburg, Germany
Intraperitoneal infusion of catumaxomab seemed to show a benefit in patients with platinum refractory epithelial ovarian cancer in a study that found that a higher dose was more beneficial. Sarah Maxwell heard from Sibylle Loibl.
Jan Vermorken
Cetuximab Benefit in Head and Neck Cancer: Final Results from EXTREME
REFERENCE: ABSTRACT 5501, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JAN VERMORKEN, University Hospital, Antwerp
New data from the EXTREME study underline the benefit achieved by cetuximab in recurrent or metastatic head and neck cancer. Following the overall survival data released at the 2007 ASCO Annual Meeting, Jan Vermorken presented progression-free survival, response rate, and quality-of-life data at the Barcelona meeting of ECCO. Derek Thorne discussed these final results with him.
JAN VERMORKEN, University Hospital, Antwerp
New data from the EXTREME study underline the benefit achieved by cetuximab in recurrent or metastatic head and neck cancer. Following the overall survival data released at the 2007 ASCO Annual Meeting, Jan Vermorken presented progression-free survival, response rate, and quality-of-life data at the Barcelona meeting of ECCO. Derek Thorne discussed these final results with him.
Jordon Berlin
David Cunningham
Molecular Markers Refine the Choice of Targeted Therapy for Metastatic Colorectal Cancer
REFERENCE: ABSTRACTS 3019, 7LB and 3014
JORDON D BERLIN, Vanderbilt University, Nashville
COMMENT: DAVID CUNNINGHAM, Royal Marsden Hospital, London
For patients with metastatic colorectal cancer, clinical outcome of anti-epidermal growth factor receptor therapy can be predicted by testing for the molecular marker K-ras. This could help patients choose between agents such as cetuximab and panitumomab. Peter Goodwin heard findings from Jordon Berlin, and asked David Cunningham about the clinical relevance.
JORDON D BERLIN, Vanderbilt University, Nashville
COMMENT: DAVID CUNNINGHAM, Royal Marsden Hospital, London
For patients with metastatic colorectal cancer, clinical outcome of anti-epidermal growth factor receptor therapy can be predicted by testing for the molecular marker K-ras. This could help patients choose between agents such as cetuximab and panitumomab. Peter Goodwin heard findings from Jordon Berlin, and asked David Cunningham about the clinical relevance.
Jonathan Cubitt
Intensive Care Units: No Hope for Patients With Hematologic Malignancy and Multiple Organ Failure?
REFERENCE: ABSTRACT 6022, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JONATHAN CUBITT, Royal Marsden Hospital, London
Intensive care units should consider admitting patients even if they have both hematologic malignancy and multiple organ failure because their chance of survival is higher than previously thought. Anna Lacey heard from Jonathan Cubitt of the Royal Marsden Hospital in London.
JONATHAN CUBITT, Royal Marsden Hospital, London
Intensive care units should consider admitting patients even if they have both hematologic malignancy and multiple organ failure because their chance of survival is higher than previously thought. Anna Lacey heard from Jonathan Cubitt of the Royal Marsden Hospital in London.
Peter Boyle
Cancer Control Works: Priorities for More Success
REFERENCE: ECCO Press Briefing, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
PETER BOYLE, International Agency for Cancer Research, Lyon
Simple measures including smoking-cessation programs and breast and cervical cancer screening have reduced cancer mortality in wealthy countries. But these types of measures need to be exported to poor countries to reduce the global cancer burden. Peter Boyle spoke in Barcelona to Peter Goodwin.
PETER BOYLE, International Agency for Cancer Research, Lyon
Simple measures including smoking-cessation programs and breast and cervical cancer screening have reduced cancer mortality in wealthy countries. But these types of measures need to be exported to poor countries to reduce the global cancer burden. Peter Boyle spoke in Barcelona to Peter Goodwin.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Similar Interviews
Post a comment
Health For All 30 Years After Alma Ata? Mental Health And War»
AliaIbrahim Zai, Egbert Sondorp, Gill Walt, Lucy Gilson, Ravi Narayan, Richard Horton, Vikram Patel, Willem Van De Put
Two important symposia have been held in London to discuss healthcare issues posing significant dilemmas to world leaders in the 21st Century. "The Future of Primary Health Care" was attended by public health experts from around the Globe to assess the best options for improving primary health care in the future. It was held on the 30th anniversary of the Alma Ata Declaration made in 1977 which was intended as a blueprint for health provision and identified primary health care as the means through which the global goal of "Health for All" could be achieved. The second meeting, on "Mental Health in Fragile States", was held to raise the profile of mental health care in zones where conflict has taken place or is still happening. Analyses of the key issues and how to deal with them effectively were discussed by top experts from the London School of Hygiene and Tropical Medicine and associated organisations. Peter Goodwin attended both meetings and talked with some of the key speakers.AliaIbrahim Zai, Egbert Sondorp, Gill Walt, Lucy Gilson, Ravi Narayan, Richard Horton, Vikram Patel, Willem Van De Put
LSHTM Audio News: British Association Special Edition»
Astrid Fletcher, Jo Lines, Sari Kovats, Colin Sutherland, Michel Coleman
Peter Goodwin hears from London School of Hygiene and Tropical Medicine experts speaking at the annual science festival of the British Association for the Advancement of Science held in Liverpool, September 6-10, 2008, and from recent scientific publications on: the health impact of global warming, a tropical virus reaching temperate zones, inequalities in cancer outcomes, how eating oily fish can save your eyesight, and free internet publishing scientific journals.Astrid Fletcher, Jo Lines, Sari Kovats, Colin Sutherland, Michel Coleman
© 2008 Audio Medica - Medical Audio News Interviews & Podcasts. 
[...] cancer mortality in wealthy countries. But these types of measures …article continues at admin brought to you by cancer.medtrials.info and [...]
[...] a higher dose was more beneficial. Sarah Maxwell heard from Sibylle Loibl. …Original post by admin delivered by Medtrials and [...]
[...] Audio Journal of Oncology in Advance - October 1st, 2007But these types of measures need to be exported to poor countries to reduce the global cancer burden. Peter Boyle spoke in Barcelona to Peter Goodwin. To listen this episode please go to ASCO Audio Journal of Oncology in Advance … [...]